NEW YORK (GenomeWeb News) – Bioinformatics firm Maverix Biomics today announced it raised $6 million in a Series A financing round to support the continued commercialization of its recently launched data analysis platform.

The financing was led by Asset Management Ventures and individual investors Andreas Bechtolsheim and Andrew Yang. In conjunction with the financing, Yang and Louis Lange, a general partner at Asset Management, have joined Maverix's board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.